Manning & Napier Advisors LLC reduced its stake in Eli Lilly and Co (NYSE:LLY) by 7.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,077 shares of the company’s stock after selling 1,725 shares during the quarter. Manning & Napier Advisors LLC’s holdings in Eli Lilly and were worth $1,973,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also bought and sold shares of the company. Pathstone Family Office LLC grew its holdings in shares of Eli Lilly and by 100.0% in the second quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock worth $4,774,000 after purchasing an additional 29 shares during the last quarter. Vantage Financial Partners Ltd. Inc. bought a new position in shares of Eli Lilly and in the second quarter worth approximately $494,000. Acrospire Investment Management LLC grew its holdings in shares of Eli Lilly and by 16.7% in the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares during the last quarter. MPS Loria Financial Planners LLC bought a new position in shares of Eli Lilly and in the second quarter worth approximately $128,000. Finally, San Francisco Sentry Investment Group CA bought a new position in shares of Eli Lilly and in the second quarter worth approximately $129,000. 76.31% of the stock is currently owned by hedge funds and other institutional investors.
In other news, SVP Susan Mahony sold 36,585 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the sale, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at approximately $4,729,989.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total value of $17,640,000.00. Following the sale, the insider now directly owns 123,084,104 shares in the company, valued at $10,856,017,972.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 251,088 shares of company stock valued at $22,041,236. 0.20% of the stock is currently owned by corporate insiders.
Several brokerages have recently issued reports on LLY. BMO Capital Markets restated a “sell” rating and issued a $71.00 target price on shares of Eli Lilly and in a report on Thursday, September 28th. Cowen reiterated a “buy” rating and issued a $95.00 price target on shares of Eli Lilly and in a report on Wednesday, October 4th. Piper Jaffray Companies reiterated a “buy” rating and issued a $105.00 price target on shares of Eli Lilly and in a report on Friday, October 13th. Morgan Stanley set a $86.00 price objective on Eli Lilly and and gave the company a “hold” rating in a research report on Friday, October 6th. Finally, Goldman Sachs Group reissued a “buy” rating and set a $95.00 price objective (up previously from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $92.14.
Eli Lilly and Co (NYSE:LLY) traded up $0.59 during trading on Friday, hitting $86.98. The company’s stock had a trading volume of 2,730,000 shares, compared to its average volume of 3,260,000. The company has a market cap of $95,770.00, a P/E ratio of 41.42, a P/E/G ratio of 1.62 and a beta of 0.35. Eli Lilly and Co has a 1-year low of $74.00 and a 1-year high of $89.09. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.02. The business had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.88 EPS. equities research analysts forecast that Eli Lilly and Co will post 4.22 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be paid a dividend of $0.5625 per share. The ex-dividend date is Wednesday, February 14th. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.59%. Eli Lilly and’s payout ratio is 99.05%.
COPYRIGHT VIOLATION WARNING: This story was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.thelincolnianonline.com/2018/01/13/manning-napier-advisors-llc-has-1-97-million-holdings-in-eli-lilly-and-co-lly-updated-updated.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.